PD-L1 and BCG response prediction

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

The programmed death-1 (PD-1), a coinhibitory receptor expressed on activated T cells and B cells, is demonstrated to induce an immune-mediated response and play a critical role in tumor initiation and development. The cancer patients harboring PD-1 or PD ligand 1 (PD-L1) protein expression have often a poor prognosis and clinical outcome. Currently, targeting PD-1 pathway as a potential new an...

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary and acquired resistance becomes one of the major obstacles, which greatly limits the long-lasting effects and wide application of PD-1/PD-L1 block...

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients

PD-L1 and intratumoral immune response in breast cancer

PURPOSE PD-L1 is thought to play an important role in the antitumor immune response. In this study, we investigated the expression of PD-L1 within breast tumor subsets to better define its prognostic significance. METHODS Immunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast ...

PD-L1, Inflammation and Glioblastoma

The PD-L1 protein has an extracellular domain, a transmembrane domain and an intracellular domain. The extracellular domain (ECD) of the PD-L1 protein is comprised of IgC–like and IgV-like domains [2]. The ECD of PD-L1 interacts with the programmed death 1 (PD-1, also known as PDCD1) and B7.1 receptors. Blocking of the PD-L1 molecule with antibodies blocks cancer cells from killing cytotoxic T ...